Improving on earlier models is how you finally get it right.Everyone here drooled over AM-101 and AUT00063 at the time. Hype was strong. Both failed.
I can't speak to AM-101 (which may just be an ill advised concept in general for anything not extremely acute), but I corresponded with one of the Autifony researchers and she is convinced the drug works, but is not specific enough (safer than Trobalt but a similar problem). They haven't given up on the drug at all btw and are still working on reformulation.
I can't think of one medical advancement they got right on the first try except for things that already occurred naturally (e.g., Penicillin). Imagine telling the Wright Brothers, their past failures meant they shouldn't believe in their eventual chances for success. Every improvement gets you closer.
Anyway, I get not wanting to "hype" things but when the science is there, there is reason for optimism.
I wasn't here when people drooled over AM-101, but I doubt I would have been one of them. If you look through my history, you will see that I was negative about:
Audion, Novartis and I hardly ever even visited the Lenire thread because the science was wishy washy and unclear to me.
I also think OTO-313 will be mostly useful acutely (with a few exceptions).
I think Neuralink is mostly hype (at least where it is anytime in the near future), too.
But I do think the science is absolutely there for FX-322 and OTO-413. Any problems that they have seem to be correctable formulation ones.